Cerebrolysin

Dr. Pradeep Albert discusses cerebrolysin as a neuropeptide growth factor containing three growth factors. He reports running a clinical trial using cerebrolysin on patients with recent ischemic strokes, noting it addresses the stroke penumbra where no other treatment exists. For healthy aging individuals with ischemia, he recommends cerebrolysin IV infusion for cognitive improvement. Cautions that fast IV infusion can cause heart arrhythmia in patients with heart conditions — must be under physician guidance. He combines cerebrolysin with intranasal mesenchymal stem cells and intrathecal administration for a three-pronged approach.

The speaker explains that Cerebrolysin's approximately 50-peptide composition creates an insurmountable regulatory obstacle in the United States, as each individual peptide would require its own separate FDA authorization process. This is estimated to take 50–70 years, making commercial approval economically and practically unviable. As a result, patients seeking this treatment must travel abroad.

Cerebrolysin is described as a mixture of approximately 50 different peptides that functions to repair neurons. It is widely used in Austria as a standard-of-care treatment for traumatic brain injury and stroke, administered at high doses in hospital settings. The speaker notes it is not available in the United States due to regulatory barriers.

Prospective single-blind controlled cohort (n=340) from Thailand. Cerebrolysin 30mL/day IV for 10 days in moderate TBI with nonoperative ICH. Significant improvement in CRS-R scores at discharge (20.3±2.7 vs 16.4±2.1, p=0.013), higher Barthel Index, lower mRS, improved 6-month survival (59.4% vs 27.8%, p<0.001). No increased adverse events. Limitation: non-randomized, single-blind.

Longevity medicine physician discusses Cerebrolysin as standard TBI/stroke treatment in Austria. Notes it's a mix of ~50 peptides that repairs neurons, unavailable in US due to regulatory burden of approving each peptide individually. Highlights gap between international and US availability.

Reconstitution protocol for 60mg lyophilized Cerebrolysin: Add 3.0 mL bacteriostatic water (inject slowly down vial wall, gently swirl, do not shake) → 20 mg/mL concentration. SubQ injection at 45-90°. Titration: Week 1: 20mg/day (100 units/1.0mL once daily); Week 2: 24mg/day (60 units AM + 60 units PM); Week 3: 28mg/day (70u AM + 70u PM); Week 4+: 32mg/day (80u AM + 80u PM). Split doses >100 units into AM/PM at different sites. Cycle: 8-12 weeks (optional 16). Insulin syringe: 1 unit = 0.01mL = 200mcg. Storage post-reconstitution: 2-8°C, use within 7 days, protect from light, do not freeze. Lyophilized vials stored at ≤25°C.

EliteBioGenix sells Cerebrolysin as lyophilized powder in 50mg and 60mg vials. Storage: 2-8°C or -20°C, protect from light, avoid repeated freeze-thaw. No reconstitution instructions provided on product page. In-vitro research concentrations referenced: 2.5-50 µg/mL (cell culture). Product labeled for in-vitro research/laboratory use only. No human dosing, reconstitution ratios, or injection route guidance included.

Cerebrolysin is a complex neuropeptide mixture (not a single peptide) derived from enzymatic hydrolysis of porcine brain tissue. Composition: ~75% free L-amino acids + ~25% low-MW neuropeptides (BDNF, NGF, CNTF, GDNF fragments). Crosses BBB due to <10kDa molecular weight. Approved in 44+ countries (EU, Asia) for stroke/AD/TBI — NOT FDA approved. Benefits: neuroprotection, neurogenesis, BDNF upregulation, synaptic regeneration, dendritic density, anti-inflammatory, antioxidant, mitochondrial energy optimization. Clinical evidence: meta-analysis of 9 RCTs for stroke recovery (PMID 29248999); 6 RCTs for Alzheimer's (PMID 21679156, effect size comparable to cholinesterase inhibitors but Cochrane quality rating = very low); 2025 review of 10 TBI studies (1900+ patients). Dosage: 5mL/day (cognitive support/biohacking), 10-20mL/day (neurological recovery). Cycle: 10-20 days on, then off. ROA: IV infusion (20-60 min slow drip) or IM. Pre-made solution — no reconstitution needed. WARNINGS: porcine-derived (contraindicated in pork allergy, anaphylaxis risk), rare seizures in predisposed individuals, severe hypotension with rapid IV infusion.